AUG 13, 2021 7:30 AM PDT

Breast Cancer Drug Reverses Deadly Blood Cancer in Mice

WRITTEN BY: Annie Lennon

A drug currently used to treat advanced breast cancers may treat a rare type of leukemia known as myelofibrosis. The study was published in Cancer Research by scientists at the University of Virginia Health System. 

Myelofibrosis is a form of leukemia- cancer of the blood and bone marrow. It typically occurs in those who are middle-aged or older and affects between 1 and 1.5 in every 100,000 people. Those with advanced stages of the disease have a median survival time of 1.5 to 2.3 years. 

Ruxolitinib, a kinase inhibitor, is used to relieve symptoms of the disease. The drug, however, does not address the disease's characteristic feature, bone marrow scarring. Scarring both disrupts the marrow's production of red blood cells- causing severe anemia- and reduces the number of platelets in the blood, making clotting difficult and enlarging the spleen. 

Previous studies have found that palbociclib, a cyclin-dependent kinase (CDK) inhibitor, reduces activity in the bone marrow of patients with advanced stages of breast cancer. Researchers thus sought to see how patients with myelofibrosis would respond to the drug.

In experiments involving mouse models of myelofibrosis, the researchers showed that palbociclib was able to reduce bone marrow scarring. It also decreased excessive levels of white blood cells and shrank their enlarged spleens. 

They then found that, when combined with ruxolitinib, palbociclib was able to restore bone marrow in mice, normalize white blood cell counts, and further reduce the size of enlarged spleens. 

"A combinatorial therapeutic approach involving palbociclib and ruxolitinib will enable lowering the doses of each of the inhibitors and thus reducing toxicities while enhancing the therapeutic efficacy," wrote the researchers in their paper. 

"The findings from this study are very exciting, and they support the clinical investigation of palbociclib and ruxolitinib combination in patients with myelofibrosis," said Golam Mohi, one of the authors of the paper. 

 

Sources:  Cancer ResearchMPN ConnectScience Daily

About the Author
  • Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
OCT 05, 2021
Drug Discovery & Development
Drug repurposing for COVID-19
OCT 05, 2021
Drug repurposing for COVID-19
The coronavirus disease that began in 2019 (COVID-19) has infected nearly 235 million individuals and led to t ...
OCT 08, 2021
Cannabis Sciences
The Synergistic Mystery of the Entourage Effect
OCT 08, 2021
The Synergistic Mystery of the Entourage Effect
The entourage effect is a much talked about characteristic attributed with the unique psychoactive effects associated wi ...
OCT 28, 2021
Cannabis Sciences
What do Student Doctors and Medical Professionals Think of Cannabis?
OCT 28, 2021
What do Student Doctors and Medical Professionals Think of Cannabis?
In the current environment the legalization of cannabis, and its use for medicinal purposes, has been a divisive topic o ...
NOV 05, 2021
Cannabis Sciences
Advances in Medical Cannabis for Treating Autism Spectrum Disorder
NOV 05, 2021
Advances in Medical Cannabis for Treating Autism Spectrum Disorder
Encouraging clinical evidence has recently sparked an emerging interest in the use of CBD-enriched medical cannabis as a ...
NOV 08, 2021
Drug Discovery & Development
A case study of CBD's tumor shrinking potential
NOV 08, 2021
A case study of CBD's tumor shrinking potential
A recent article published in the British Medical Journal reported the case of a woman who shrank a tumor by taking CBD. ...
NOV 29, 2021
Genetics & Genomics
A CRISPR-Based Technique to Make New Antibiotics
NOV 29, 2021
A CRISPR-Based Technique to Make New Antibiotics
There are many bacterial organisms, and they can live cooperatively, or they can battle one another. They are also capab ...
Loading Comments...